Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ContextVision ABOSL:CONTX +3.98%82 EV-to-EBIT is 32.25 as of Jul. 26, 2026, which is 53% above its 10-year median of 21.14. GuruFocus rates OSL:CONTX with a GF Score™ of 82/100 and a GF Value™ of kr5.11 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 471 Healthcare Providers & Services companies, ContextVision AB ranks worse than 78.13% on this metric.
The historical rank and industry rank for ContextVision AB's EV-to-EBIT or its related term are showing as below:
OSL:CONTX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -899.87 Med: 21.14 Max: 527.26
Current: 32.25
During the past 13 years, the highest EV-to-EBIT of ContextVision AB was 527.26. The lowest was -899.87. And the median was 21.14.
OSL:CONTX's EV-to-EBIT is ranked worse than 78.13% of 471
companies
in the Healthcare Providers & Services industry
Industry Median: 15.84
vs OSL:CONTX: 32.25
ContextVision AB (OSL:CONTX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ContextVision AB's Enterprise Value for the quarter that ended in Mar. 2026 was kr197.8 Mil.
ContextVision AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr6.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ContextVision AB EV-to-EBIT Related Terms
ContextVision AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for ContextVision AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:CONTX vs VEEV, BTSG, TEM: EV-to-EBIT Comparison
For the Health Information Services subindustry, ContextVision AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ContextVision AB EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ContextVision AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ContextVision AB's EV-to-EBIT falls into.
ContextVision AB's current Enterprise Value is kr196.9 Mil.
ContextVision AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr6.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ContextVision AB (OSL:CONTX) has a EV-to-EBIT of 32.25 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ContextVision AB and its competitors. This is 53% above median its historical median of 21.14. According to the industry distribution chart, ContextVision AB ranks #368 out of 471 companies in the Healthcare Providers & Services industry, placing it in the top 78.1%.
Is ContextVision AB's EV-to-EBIT too high?
ContextVision AB's current EV-to-EBIT of 32.25 is 53% above median its 10-year median of 21.14. The Healthcare Providers & Services industry median EV-to-EBIT is 15.84. ContextVision AB's value of 32.25 is 103.6% above this industry median. Based on the distribution chart, ContextVision AB ranks #368 out of 471 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, ContextVision AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ContextVision AB's EV-to-EBIT compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ContextVision AB ranks #368 out of 471 companies for EV-to-EBIT. This places ContextVision AB in the lower half of its industry. The industry median EV-to-EBIT is 15.84. ContextVision AB's value of 32.25 is 103.6% above this benchmark. While the company's 10-year median is 21.14 vs. the industry median of 15.84, ContextVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ContextVision AB's current EV-to-EBIT of 32.25 is 103.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ContextVision AB and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ContextVision AB's current EV-to-EBIT is 32.25, which is 53% above median its own 10-year median of 21.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ContextVision AB stock overvalued right now?
Based on GuruFocus' analysis, ContextVision AB (OSL:CONTX) is currently considered Significantly Undervalued. The stock's GF Value™ is kr5.11, compared to a current price of kr3.40 — trading 33.5% below its estimated fair value. The current EV-to-EBIT is 32.25, which is 53% above median its 10-year median of 21.14 and 103.6% above the Healthcare Providers & Services industry median of 15.84. ContextVision AB's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ContextVision AB (OSL:CONTX), the current EV-to-EBIT is 32.25 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ContextVision AB (OSL:CONTX) Overvalued in 2026?
Based on GuruFocus' analysis, ContextVision AB stock appears to be undervalued.
The current stock price of kr3.40 is trading 33.5% below its estimated GF Value™ of kr5.11.
GuruFocus considers ContextVision AB to be Significantly Undervalued.
Key valuation signals for OSL:CONTX:
EV-to-EBIT: 32.25 (53% above median its 10-year median of 21.14)
GF Value™: kr5.11 vs. price of kr3.40 (33.5% below fair value)
Industry Position: 103.6% above the Healthcare Providers & Services median (#368 of 471)
No single metric tells the full story. See the OSL:CONTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ContextVision AB is a medical technology company. It develops and sells image enhancement software for medical diagnosis and artificial intelligence. Its product portfolio includes image enhancement software for 2D/3D/4D (dimensional) ultrasound, magnetic resonance imaging (MRI), X-Ray, radiography, and mammography. Its geographical segments are Asia, Europe, and America.
82GF Score
Get the complete analysis for OSL:CONTX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:CONTX has been successfully added to your 
